ADDRESSING COMPLEX BIOLOGICS WITH RATIONAL DRUG DEVICE DESIGN
SHL's Gene Rhode Fuensalida Pantig reviews drug development over the years, the discovery of biologics as therapeutic agents and the emergence of autoinjectors. In correspondence, Hans Lin, PhD, Research Fellow at Academia Sinica, Taiwan, discusses the inherent properties of biologics that should be of prime consideration to industry.
Andreas Schneider highlights how the ever-increasing interest in device platforms raises concerns around the broad availability of lookalike autoinjectors that may result in inappropriate medication usage. He summarises a recent empirical study1 providing insights into which device attributes drive device distinguishability.